ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!REGN Company Profile and Key Details
Regeneron Pharmaceuticals, Inc.
REGN Stock Price Chart
Stock Price Today
Regeneron Pharmaceuticals, Inc. (REGN) stock surged +0.62%, trading at $700.33 on NASDAQ, up from the previous close of $696.02. The stock opened at $697.74, fluctuating between $693.57 and $704.01 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Company Information
| Employees | 15106 |
| Beta | 0.08 |
| Sales or Revenue | $14.20B |
| 5Y Sales Change% | 1.103% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock price is $700.33 in the last trading session. During the trading session, REGN stock reached the peak price of $704.01 while $693.57 was the lowest point it dropped to. The percentage change in REGN stock occurred in the recent session was 0.62% while the dollar amount for the price change in REGN stock was $4.31.
The NASDAQ listed REGN is part of Biotechnology industry that operates in the broader Healthcare sector. Regeneron Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Joseph J. LaRosa
Executive Vice President, Gen. Counsel & Sec.
Mr. Robert E. Landry Jr.
Executive Vice President of Fin. & Chief Financial Officer
Dr. Andrew J. Murphy Ph.D.
Executive Vice President of Research
Ms. Patrice Gilooly
Senior Vice President of Quality Assurance & Operations
Mr. Christopher R. Fenimore
Senior Vice President, Head of Accounting & Controller
Mr. Bob McCowan
Senior Vice President of IT & Chief Information Officer
Mr. Daniel P. Van Plew
Executive Vice President and GM of Industrial Operations & Product Supply
Mr. Gerald Underwood
Senior Vice President of Technical Operations
Dr. Leonard S. Schleifer M.D., Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Dr. George D. Yancopoulos M.D., Ph.D.
Co-Founder, Pres, Chief Scientific Officer & Co-Chairman
Ms. Marion E. McCourt
Executive Vice President of Commercial
REGN's closing price is 9.09% higher than its 52-week low of $642.00 where as its distance from 52-week high of $1,211.20 is -42.18%.
Number of REGN employees currently stands at 15,106.
Official Website of REGN is: https://www.regeneron.com
REGN could be contacted at phone 914 847 7000 and can also be accessed through its website. REGN operates from 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, United States.
REGN stock volume for the day was 727.32K shares. The average number of REGN shares traded daily for last 3 months was 889.14K.
The market value of REGN currently stands at $75.29B with its latest stock price at $700.33 and 107.51M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com